Table 1—

Baseline demographics and characteristics of randomly assigned patients

PPTBBTP
n187187
Age (years)55.4 ± 9.854.0 ± 9.20.163
Sex (male:female)99 (53):88 (47)98 (52):89 (48)1.000
Race/ethnicity
    Caucasian103 (55.1)102 (54.6)1.000
    Hispanic49 (26.2)53 (28.3)0.728
    Black/African descent25 (13.4)18 (9.6)0.331
    Other10 (5.3)14 (7.5)0.528
Weight (kg)99.1 ± 19.899.8 ± 21.30.676
BMI (kg/m2)34.1 ± 5.334.8 ± 5.50.227
Diabetes duration (years)10.9 ± 6.311.2 ± 6.20.625
A1C (%)8.83 ± 1.048.89 ± 1.090.598
FPG [mg/dl (mmol/l)]171.81 ± 59.79 (9.54 ± 3.32)181.48 ± 59.74 (10.08 ± 3.32)0.119
Total daily glargine dose     at study entry [units     (units/kg)]52.5 ± 24.1 (0.53 ± 0.21)54.9 ± 27.8 (0.56 ± 0.27)0.382
Concomitant OHAs at     study entry
    Met/Sulf/TZD25 (13.4)23 (12.3)0.877
    Met/Sulf79 (42.2)68 (36.4)0.290
    Met/TZD19 (10.2)16 (8.6)0.723
    Sulf/TZD3 (1.6)12 (6.4)0.032
    Metformin30 (16.0)29 (15.5)1.000
    Sulfonylurea23 (12.3)28 (15.0)0.547
    TZD6 (3.2)8 (4.3)0.786
Concomitant OHAs     during the study
    Met/TZD37 (19.8)36 (19.3)1.000
    Metformin101 (54.0)89 (47.6)0.255
    TZD10 (5.3)17 (9.1)0.230
  • Data are means ± SD or n (%) unless otherwise indicated. Met, metformin; Sulf, sulfonylurea; TZD, thiazolidinedione.